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ABSTRACT 
The aim of the present work was development and characterization of  in-situ Ophthalmic Gel of  Bepotastine Besilate to overcome the 
drawbacks obtained by conventional eye drop. There are two independent variables were used i.e. Carbopol 934 and HPMC K100. Carbopol 934 
were used as gelling agent and HPMC K100 were used as bioadhesive polymer. The in situ gelling system involves sol-to-gel transition in the 
cul-de-sac upon instillation to avoid pre corneal elimination. The formulations were prepared by 32 factorial design. The prepared formulations 
were evaluated for Clarity, pH, Viscosity, Bioadhesive strength of gel, Gel strength , Drug Content, In-vitro Drug Release Study,  Isotonicity 
Evaluation, HET-CAM Test and stability studies. The drug content was in the range of 97-99.57 %. Formulation F5 selected as optimized on the 
basis of evaluation. It shows highest drug release upto 8 hours. It shows good antihistaminic activity against Staphylococcus aureus. The 
optimized formulation was isotonic with blood cells. It passes sterility test. The optimized formulation passes the ocular irritancy test i.e. HET-
CAM Test. The formulation kept for the stability study for 3 months. Short term stability study indicates that room temperature 400±20 was 
appropriate storage condition for formulations.  
Keywords:  pH Triggered, bioadhesive polymer, Carbopol 934, HPMC K100, HET-CAM Test , Isotonicity Evaluation. 
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INTRODUCTION 
One of the most challenging and interesting drug delivery is 
ophthalmic drug delivery for the pharmaceutical scientist. 
The anatomy, biochemistry and physiology of the eye render 
this organ delicately impermeable to foreign substances. To 
evade the protective barriers of the eye the challenge to the 
formulator is to circumvent the protective barriers of the 
eye without causing permanent tissue damage. The 
development of newer more sensitive diagnostic techniques 
and therapeutic agents render urgency to the development 
of more successful ocular delivery system.(1) Ocular 
disposition and elimination of a therapeutic agent is 
dependent upon physicochemical, microbiological, 
pharmaceutical properties and ophthalmic irritancy 
properties of ocular dosage forms as well as the relevant 
ocular anatomy and physiology. Generally topical 
application of drugs is the method of choice under most 
circumstances because of its convenience and safety for 
ophthalmic chemotherapy.(2) Ophthalmic delivery system is 
a challenging area for the formulation chemist due to unique 
anatomy and physiology of the eye. The anatomy and 
physiology of the eye render this organ delicately 
impervious to foreign substances. The challenge to the 
formulator is to avoid the protective barriers of the eye 
without causing permanent tissue damage.(3) This problem 
can be overcome by using In-situ gel forming ophthalmic 
drug delivery systems prepared from polymers that exhibit 
reversible phase transition and pseudo-plastic behaviour to 
minimize interference with blinking. In situ gel forming drug 
delivery is a type of mucoadhesive drug delivery system. 
Such system can be formulated as liquid dosage form 
suitable for administration by instillation in to the eye which 
upon exposure to the eye shift to the gel phase depends 
upon physiological pH condition of eye. The various 
approaches that have been attempted to increase the 
bioavailability and the duration of the therapeutic action of 
ocular drugs can be divided into two categories. The first 
one is based on the use of sustained drug delivery systems 
which provide the controlled and continuous delivery of 
ophthalmic drugs.(4) 
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MATERIALS AND METHODS  
Bepotastine Besilate was obtained from Precise Chemi pharma pvt ltd. Ghatkoper West, Mumbai, India as a gift sample. 
Carbopol 934 and HPMC K100 were purchased from Research-Lab Fine Chem. Industry –Mumbai. 
Development of Bepotastine Besilate Ophthalmic Gel: 
Composition of formulation batches as per 32 factorial designs shown in Table 1. 
Table 1: Composition of Formulation Batches as per 32 Factorial Design 
Formulation code 
   
 
F1 
 
 
F2 
 
 
F3 
 
 
F4 
 
 
F5 
 
 
F6 
 
 
F7 
 
 
F8 
 
 
F9 
 
Bepotastine  Besilate 
(w/v) 
1.5 
 
1.5 
 
1.5 
 
1.5 
 
1.5 
 
1.5 
 
1.5 
 
1.5 
 
1.5 
 
HPMC K100 
(w/v) 
 
0.6 
 
0.8 
 
1 
 
0.6 
 
0.8 
 
1 
 
0.6 
 
0.8 
 
1 
Carbopol 934 
(w/v) 
 
0.1 
 
0.1 
 
0.1 
 
0.2 
 
0.2 
 
0.2 
 
0.3 
 
0.3 
 
0.3 
Monobasic sodium 
phosphate (w/v) 
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Disodium edetate 
(w/v) 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
Benzalkonium 
Chloride (w/v) 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
Purified water (ml) 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
Formulation of Ophthalmic in situ Gel: 
The quantities of drug and other ingredients were weighed 
as per (table no.1) and formulations were prepared in 
following manner :(5) 
 Cleaning of glassware and container: All the 
glassware’s were washed with distilled water and then 
sterilized by drying at 160-165°C for 1 hour in hot air 
oven. 
 Preparation of solution ‘A’: Accurately weighed 
quantity (1.5gm) of the Bepotastine besilate was 
dissolved in 50ml phosphate buffer (pH6.8). 
 Preparation of polymer dispersion ‘B’: The Carbopol 
934 and HPMC K100 was dissolved in distilled water 
was allowed to hydrate for 24 hours to produce a clear 
solution. The Benzalkonium chloride and Disodium 
edetate was added to the above polymer dispersion. 
 Mixing of ophthalmic formulation: The solution ‘A’ 
and solution ‘B’ was mixed with continued stirring and 
pH of formulation was maintained using 0.1N NaOH. 
 Sterilization of ophthalmic formulation:  repared 
solutions were autoclaved at     C for    min  
 Aseptic filling to container: The formulation was 
aseptically transferred to previously sterilized glass 
bottles and sealed. 
Evaluation of Ophthalmic In-situ Gel Formulation: 
Evaluation of in-situ ophthalmic gel of Bepotastine 
Besilate 
1. Physical parameter:  
Clarity: 
The formulations were visually checked for the clarity. 
pH:  
pH of each formulation was determined by using Digital pH 
meter (Sistronic Digital pH meter 335). This    was 
previously calibrated by pH 4 and pH 7. The pH values were 
recorded immediately after preparation.  
2. Rheological study: 
Viscosity: 
The rheological properties of gels were determined by the 
Brookfield viscometer; type DV-II + PRO    using spindle 
no.61& 63.Viscosity of the formulations were taken at two 
different pH 6.8 and at pH7.4. 
3. Measurement of the gel strength: 
 A sample of 25 mL of the gel was put in a 50 mL graduated 
cylinder. A weight of 14.33 g was placed on  the gel surface. 
The gel strength which is an indication for the ophthalmic 
gel at physiological temperature was determined by the time 
in seconds required by the weight to penetrate 5 cm into the 
gel.(6)All measurements were performed in triplicate (n=3). 
The apparatus used for measuring gel strength is shown in 
Fig.1 
 
Fig.1: Gel strength measuring device 
(A): Weights (B): Device (C): Graduated cylinder (D): Gel. 
     Ingredients (%) 
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4. Bioadhesive Strength 
“Detachment Stress is the force required to detach the two 
surfaces of mucosa when a formulation/gel is placed in 
between them”  The detachment stress was measured by 
using a modified analytical balance (A). A fresh goat 
membrane was obtained from local slaughter house. A 
section of fresh mucosa was cut from the goat eye and 
washed with saline solution.(7) 
i) Fabrication of equipment:  
The equipment was fabricated by us in the laboratory as 
shown in figure 3. A double beam physical balance was taken 
both the pans were removed. The left pan was replaced with 
a brass wire to which was hanged a teflon disc (D) also 
locally fabricated. The dimensions are 2 cm height and 
include an expanded cap of diameter 3.8 cm and thickness 2 
cm. Another teflon disc of 2 cm height and 1.5 cm diameter 
was placed right below the suspended disc upon the base of 
the balance. The right pan (B) was replaced with a lighter 
pan so that the left pan weighs 5.25 gm more than the right 
pan. The lower Teflon block was intended to hold the 
mucosal tissue (E) of goat corneal membrane and to be 
placed in a beaker containing simulated tear fluid pH 7.4.(7)   
ii) Measurement of adhesion force:   
Goat corneal membrane was obtained commercially; the 
cornea was collected into a sterile container containing 
sterile buffer solution of pH 7.4. The corneal membrane 
brought was stored in a refrigerator until use. The following 
procedure was used for all the test formulations using the 
above equipment. The goat corneal membrane was removed 
from refrigerator and allowed to attain equilibrium with 
ambient conditions in the laboratory. The goat corneal 
membrane was carefully excised without removing 
connective and adipose tissue and washed with simulated 
tear fluid solution. The tissue was stored in fresh simulated 
tear fluid solution. Immediately afterwards the membrane 
was placed over the surface of lower teflon cylinder (E) and 
secured. This assembly was placed into beaker containing 
simulated nasal solution pH 7.4 at 37 ± 2°C. From each batch 
some quantity of gel was taken and applied on the lower 
surface of the upper teflon cylinder. The beaker containing 
mucosal tissue secured upon lower cylinder (E) was 
manipulated over the base of the balance so that the mucosal 
tissue is exactly below the upper cylinder (D). The exposed 
part of the gel was wetted with a drop of simulated tear fluid 
solution and then a weight of 10 gm was placed above the 
expanded cap left for 10 minutes. After which the gel binds 
with mucin. The weight was removed. Then slowly and 
gradually weights were added on the right side pan till the 
gel separates from the mucosal surface/ membrane. The 
weight required for complete detachment is noted (W1) 
(W1-5.25G)) gives force required for detachment expressed 
in weight in grams. Procedure was repeated for two more 
times. Average was computed and recorded.  
iii) Calibration of test equipment:    
Initially, a gel from the same batch was taken ten times and 
individual force required for complete detachment was 
noted and SD was calculated. (8)  
iv) Force of adhesion (N): 
Bioadhesive strength = (bioadhesive strength/1000) × 9.81 
Bond strength (N/m2) = force of adhesion (N)/surface area 
of disk (m2) 
 
 
Fig. 2: Modified Bioadhesion apparatus 
(A): Modified balance (B): Weighing pan (C): Weight (D): Upper 
taflon disc (E): Lower taflon disc (F): Corneal membrane 
(G):Simulated tear fluid. 
5. Drug Content 
The drug content was determined by taking 1ml of the 
formulation and diluting it to 100ml with phosphate buffer. 
Aliquot of 5 ml was withdrawn and further diluted to 25 ml 
with phosphate buffer. Bepotastine  besilate concentration 
was determined at 261nm by using UV-Visible 
spectrophotometer.(9) 
6. In-vitro Drug Release Study 
In-vitro release study of the formulated ophthalmic in-situ 
gel was carried out by using diffusion cell through egg 
membrane as a biological membrane. Diffusion cell with 
inner diameter 1.4cm was used for the study. The 
formulation 1 ml were placed in donor compartment and 
Freshly prepared 100 ml artificial tear fluid solution 
(sodium chloride 0.670g, sodium bicarbonate 0.200g, 
potassium chloride 0.248 g, calcium chloride dehydrated 
0.008g, distilled water q.s. 100ml) was placed in receptor 
compartment. Egg membranes were mounted in between 
donor and receptor compartment. The position of the donor 
compartment was adjusted so that egg membrane just 
touches the diffusion medium. The whole assembly was 
placed on the thermostatically controlled magnetic 
stirrer.(10) The temperature of the medium was maintained 
at 37°C ± 0.5°C. 2ml of sample is withdrawn from receiver 
compartment after 30 min, 1, 2, 3, 4, 5, 6, 7 & 8 h and same 
volume of fresh medium is replaced. The withdrawn samples 
was diluted to 10ml in a volumetric flask with phosphate 
buffer and analyzed by UV spectrophotometer at 261 nm.(11) 
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Fig. 3: Laboratory designed diffusion cell. 
(A): Test tube containing formulation (B): Egg membrane (C): 
Beaker containing simulated tear fluid solution (D): Magnetic 
stirrer. 
7. Isotonicity Evaluation 
The formulations were mixed with few drops of diluted 
blood on a slide. The diluted blood was prepared by using 
Grower’s solution and Slide was observed under microscope 
at 45x magnification. The shape of blood cells were 
compared with standard marketed ophthalmic 
formulation.(12,13) 
8. Test for sterility 
The sterility test was carried out as per IP (2014) method. 
The three medium were taken for this test i.e. fluid 
thioglycolate medium, Artificial fluid thioglycolate and 
soyabean casein digest medium. The three set were 
prepared each set containing three tubes of each medium. 
The first set was negative control for this sterile media is 
used second set was a positive control for this sterilized 
media inoculated with Staphylococcus aureus was used and 
third set was a test. The 1mL sterile optimized formulation 
was taken and this formulation was diluted with 100mL 
sterile water for injection from this 5mL test solution were 
added in each medium. The formulation was incubated for 
not less than    days at   -    C in fluid thioglycolate 
medium and at   -    C in soyabean casein digest medium 
to find out growth of  bacteria in formulation.(14,15) 
9. HET-CAM Test  
The Hen’s Egg Test on the Chorioallantoic membrane (HET-
CAM) is another alternative method to animal 
experimentation for assaying corrosives or sever ocular 
irritations using Chorioallantoic membrane of embryonated 
hen’s egg  This test assesses the damage to this membrane to 
determine the potential irritatation to the conjunctiva. Its 
well developed vascularization provides an ideal model for 
studies of ocular irritation.(16,17) 
                                                    9 Days fertilized hen’s eggs 
 
The CAM (25%) is treated with the test item for 30 sec. 
 
                                                         Test item was wash off 
 
                                                     Effect assessed within 5 min. 
End Point :- Redness, Irritation 
10. Stability studies 
For the stability study the formulation was taken for 3 
months. The test condition for stability study was 
temperature condition was at room temperature (400 ± 20). 
Relative humidity was 75± 5%. The formulations were 
evaluated mainly for their physical characteristics at the 
predetermined intervals of 30 days like appearance, clarity, 
pH, viscosity and drug content.(18,19) 
RESULT AND DISCUSSION 
Physical parameter 
1. Clarity 
On careful visual inspection against dark and white 
background all the prepared ophthalmic gel formulations 
were found to be free from any suspended particulate 
matter. All the formulations were found to be clear. The 
prepared formulations are as shown in Figure 4.
 
 
Fig.4: Prepared Formulation Batches 
2. pH  
The pH of all the formulations from F1 to F9 was found to be 
in the range of 6.67 to 6.84 pH values of formulations shown 
in Table 2. Ideally, the ophthalmic solutions should passes 
pH in the range of 6.5-8.5 so as to minimize discomfort or 
excessive tear flux causing faster drainage of the instilled 
dose due to corneal irritation. 
 
 
 
Table 2: pH values of formulations 
Sr. No Formulation code Observed pH (±S.D.) 
1 F1 6.83 ± 0.001 
2 F2 6.84 ± 0.001 
3 F3 6.79 ± 0.002 
4 F4 6.68± 0.004 
5 F5 6.80± 0.001 
6 F6 6.85 ± 0.001 
7 F7 6.81 ± 0.001 
8 F8 6.78 ± 0.004 
9 F9 6.67 ± 0.001 
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3. Rheological study  
Viscosity 
The Viscosity profile of formulations at pH 6.8 and pH 7.4 is 
shown in Fig.5 and Fig.6 respectively. 
Viscosity v/s rpm plots for all formulations shows decrease 
in viscosity as shear rate (rpm) was increased which indicate 
that gel has the pseudo plastic flow. As pH was increased the 
increase in viscosity was observed. Concentration of 
Carbopol934 and HPMC K-100 was a major factor affecting 
viscosity of formulations. In combination with Carbopol 934 
and HPMC K-100 was shown considerable increase in 
viscosity when concentration of Carbopol 934 is 0.3% w/v & 
HPMC K-100 is 1% w/v. 
 
Fig. 5: Viscosity profile of formulations at pH 6.8 
 
 
Fig. 6: Viscosity profile of formulations at pH7.4 
4. Measurement of the Gel Strength 
The gel strength of Ophthalmic formulations is shown in 
Table 3. 
The gel strength was found to be affected by concentrations 
of gelling agent, mucoadhesive polymers and also 
by the pH. Optimal mucoadhesive gel must have suitable gel 
strength so as to be administered easily and can be retained 
Ocular region without leakage after administration. Gel 
strength of all formulations showed comparable results as 
that of viscosity results. 
 
 
Table 3: Gel strength of formulations 
Sr. No Formulation code Gel strength (sec) 
(±S.D.) 
1 F1 0.57±0.05 
2 F2 0.62 ± 0.01 
3 F3 0.85 ±0.07 
4 F4 1.04 ± 0.05 
5 F5 1.30 ± 0.08 
 6 F6 1.51 ± 0.43 
7 F7 1.51 ± 0.41 
8 F8 2.27 ± 0.12 
9 F9 2.41 ± 0.04 
 
5. Bioadhesive strength 
The detachment stress of formulation is shown in Table  4. 
Bioadhesive force means the force with which gels bind to 
ocular mucosa. Greater bioadhesion is indicative of 
prolonged residence time of a gel and thus prevents its 
drainage from cul-de-sac. The bioadhesion force increased 
significantly as the concentration of bioadhesion polymers 
increased. The Detachment Stress was determined for 
ophthalmic gels. Results of this test indicate that the variable 
Carbopol 934 and HPMC K100 both are having effect on 
bioadhesive strength. It shows that bioadhesive force was 
increased with the increasing concentration of the Carbopol 
934 and HPMC K100. 
Table 4: Bioadhesive strength of formulations 
Formulation code Detachment Force (N) (±S.D) 
F1 0.1899 ± 0.035 
F2 0.2018±0.027 
F3 0.2525 ±0.005 
F4 0.3508 ± 0.005 
F5 0.4394 ± 0.005 
F6 0.4870± 0.005 
F7 0.5078± 0.005 
F8 0.6408 ± 0.005 
F9 0.6458± 0.0005 
6. Drug content 
The Drug content of formulations is shown in Table 5. 
The percentage drug content of all prepared ophthalmic 
formulations was found to be in the range of 97-99.57 %. 
Therefore uniformity of content was maintained in all 
formulation. 
Table 5: Percent drug content of Ophthalmic gel 
Formulation Code Drug content (%) (±S.D.) 
F1 98.85± 0.12 
F2 98.56± 0.17 
F3 98.56±0.16 
F4 98.98± 0.065 
F5 99.57± 0.17 
F6 97.68± 0.13 
F7 98.98± 0.13 
F8 98.35± 0.17 
F9 97.59± 0.12 
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 7. In-vitro drug release study 
 
Fig.7: In-vitro drug release profile of formulations 
 
Out of nine formulations maximum release after 8 hour was 
found for F5 formulation. This indicates release of 99.1 % 
drug availability. In-vitro drug release profile of 
formulations shown in Figure 6. 
8. Isotonicity Evaluation 
The shape of blood cells, blood cells with Bepotastine 
Besilate F5 and blood cells with Bepreve as marketed 
formulation are shown in figure 7. Isotonicity testing of 
Optimized formulation (F5) exhibited no change in the shape 
of blood cells. The blood cell size was found in 6-7µm range 
which reveals the isotonic nature of the formulation as 
compare with standard ophthalmic marketed preparation. 
This indicates the maintenance of tonicity in prepared 
formulations.
 
         
a.                                                                             b.                                                                      c. 
Fig.8: Shape of Blood Cells 
a, b and c are the image of blood cells, blood cells with bepotastine besilate in situ ophthalmic gel blood cells with marketed 
formulation. 
 
9. Test for sterility 
There was no appearance of turbidity and hence no evidence 
of bacterial growth when optimized formulation was 
incubated for 14 days at 30-35 c in case of fluid thioglycolate 
medium and at 20 -25 c  in case of soyabean-casein digest 
medium. The preparations examined therefore passed the 
sterility test. 
10. HET-CAM Test 
The result of ocular study indicate that the formulation F5 
was non irritant and no ocular damage or abnormal clinical 
signs were visible. The ocular irritation study on 
ChorioAllantoic membrane of Hen’s Egg’s shown in Fig  8
 
Garge et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):656-663  
ISSN: 2250-1177                                                                                  [662]                                                                                 CODEN (USA): JDDTAO 
                 
a                                                               b                                                               c 
               
d                                                              e                                                      f 
Fig. 9: The ocular irritation study on ChorioAllantoic membrane of Hen’s Egg’s 
a, b, c, d, e, f are images of the ocular irritation study on Chorioallontoic membrane of Hen’s Egg at the time of instillation, after 
1min, 2 min, 3 min, 4 min and 5 min respectively. 
11. Stability study  
Stability study of optimized F5 formulation at room temperature shown in Table 6. Formulations at room temperature were 
found to be stable upto 3 months. There is no change in drug content, pH, clarity. 
                                                    Table 6: Stability study data for F5 batch 
Sr.
No. 
Observation Before Stability 
Testing 
During Study 
30 Days 60 Days 90 Days 
1 Clarity Clear Clear Clear Clear 
2 Visual appearance Transparent Transparent Transparent Transparent 
3 pH 6.8 6.8 6.8 6.82 
4 Drug Content 99.1% 99% 99% 98.97% 
 
CONCLUSION 
1.  Preformulation evaluation study has shown the identity 
and purity of  Bepotastine Besilate. 
2.  Infrared spectroscopy studies of Bepotastine Besilate alone 
and their physical mixture with Carbopol 934 and HPMC K100 
revealed that Bepotastine Besilate is compatible with all 
polymers used. 
3.  The clarity of the prepared formulations was found 
satisfactory. 
4.  pH of all the formulations was found to be in between the 
ophthalmic pH range (6.5-8.5) which is in tolerable range in 
contact with ocular tissues. 
5.  The viscosities of the all formulations were greatly affected 
by concentration of Carbopol 934 and HPMC K100. 
6.  Gel strength and bioadhesive strength of formulations 
resembles to the viscosity results. 
7. Drug content of all formulations was found to be in between 
97-99.56% which was in acceptable range. 
8.  The release kinetics results obtained indicate that 
formulation containing 0.2%w/v Carbopol 934 and 0.8% w/v 
HPMC K100 showed highest release i.e. 99.1 after 8hours 
which indicates that the formulation have shown prolong 
release. This optimized formula was also confirmed by design 
expert 11 optimization software. 
9.  The optimized formulation has shown the maintenance of 
tonicity. 
10. The optimized formulation has passed sterility test. 
11. The optimized formulation showed no ocular irritancy. 
12.  The optimized formulation F5 showed good stability and 
no change in any physical characteristics over a 3 months 
period. 
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